Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376467 | 0.83 | CYP1A2 (0.51) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL1273221 | 0.82 | PDE10A (0.44) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| SCHEMBL1272552 | 0.81 | CYP1A2 (0.50) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| SCHEMBL7597345 | 0.79 | CYP1A2 (0.44) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| SCHEMBL1271294 | 0.76 | PDE10A (0.58) | CYP1A2LMNAPDE10AKDM4EALDH1A1 | |
| SCHEMBL1271353 | 0.75 | KDM4E (0.40) | CYP1A2LMNAKDM4EALDH1A1CA12 | |
| SCHEMBL28330248 | 0.75 | FAAH (0.43) | CYP1A2CYSLTR1CYSLTR2PDE10AKDM4E | |
| SCHEMBL10382335 | 0.75 | CYP1A2 (0.44) | CYP1A2CYSLTR1CYSLTR2GPBAR1KDM4E | |
| Sulfuric Acid SCHEMBL3119154 | 0.74 | CYSLTR1 (0.50) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL243294 | 0.74 | CYSLTR1 (0.53) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | claimed |
| US-20110281879-A1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-7893093-B2 | Sulfonyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-02-22 | — | — | US | claimed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | claimed |
| EP-1866277-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006102535-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | claimed |
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20110281879-A1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7893093-B2 | Sulfonyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | disclosed |
| EP-1866277-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006102535-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281879-A1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | CYP1A2 3666/4885CYSLTR1 608/4885CYSLTR2 639/4885 |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | CTSS, CTSF, CTSB | CYP1A2 3666/4885CYSLTR1 608/4885CYSLTR2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.